BIOABioAge Labs, Inc.
What is the market doing?
No clear lean: nothing decisive, though in a downtrend (−60% vs 200-day).
In a downtrend, below its 50- and 200-day averages. Oversold (RSI 21). Price is −60% vs its 200-day average.
Heavily shorted, settled Sep 15, 2026, about a week of normal trading to cover. Up 13% since the previous count, up from 4.7% of shares outstanding three months ago.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How BIOA is trading
BioAge Labs, Inc. is +30% over the past year while the S&P 500 is +18%: 11 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- −60%
vs 200-day average · a clear downtrend
- RSI (14)
- 21
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 74%
Below its 52-week high
Details›
- Last close2026-10-09
- $6.35
- 1 monthS&P 500 +2.7%
- −27%
- 1 yearS&P 500 +18%
- +30%
- vs 50-day average$9.42
- −33%
- 52-week high
- $24.29
- 52-week low
- $4.94
- Annualised volatility
- 102%
| Year | Return |
|---|---|
| 2026 (year to date) | −52% |
| 2025 | +128% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 1 of 2 | +11% |
| Feb | 2 | 2 of 2 | +9.1% |
| Mar | 2 | 0 of 2 | −20% |
| Apr | 2 | 1 of 2 | +4.0% |
| May | 2 | 1 of 2 | −1.6% |
| Jun | 2 | 2 of 2 | +18% |
| Jul | 2 | 1 of 2 | +1.7% |
| Aug | 2 | 1 of 2 | −22% |
| Sep | 2 | 1 of 2 | −3.1% |
| Oct | 3 | 2 of 3 | +11% |
| Nov | 2 | 1 of 2 | +2.5% |
| Dec | 2 | 1 of 2 | −15% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Drug Manufacturers, Specialty & Generic
The closest names by size in the same industry